Indivior Announces Inclusion in the S&P SmallCap 600® Index

Group 1 - Indivior PLC has been added to the S&P SmallCap 600 index, effective December 22, 2025, marking a significant milestone for the company [1][2] - The inclusion in the S&P SmallCap 600 aligns Indivior's capital markets presence with its enhanced U.S. business profile, as stated by the CEO Joe Ciaffoni [2] - The S&P SmallCap 600 index consists of 600 U.S. companies with market capitalizations between $1.2 billion and $8.0 billion, designed to track liquid and financially viable companies [2] Group 2 - Indivior Pharmaceuticals focuses on developing medicines for opioid use disorder (OUD) and aims to transform OUD into a recognized chronic disease [3] - The company is committed to expanding its portfolio of OUD treatments and has a pipeline of product candidates to enhance its offerings in this category [3]